Notice of Correction to Funding Opportunity Description for RFA-HL-16-025 "NHLBI Emerging Investigator Award (EIA) (R35)"

---

Notice Number: NOT-HL-17-569

Key Dates
Release Date: December 8, 2017

Related Announcements
RFA-HL-16-025
NOT-HL-16-302 RESCINDED

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On December 10, 2015, the NHLBI issued Funding Opportunity Announcement RFA-HL-16-025 "NHLBI Emerging Investigator Award (EIA) (R35)". The purpose of this Notice is to clarify that during the EIA project period: 1) NHLBI will not consider funding an NHLBI multiple-PD/PI grant unless it fits one of the sources of funding noted in the revised language; and 2) an EIA awardee may apply for and, if selected for funding, receive NHLBI support as a program project, subproject lead. This Notice also rescinds NOT-HL-16-302.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Overview
Current language:

Since an NHLBI EIA is intended to provide the primary, and most likely sole, source of NHLBI funding on individual grant awards, most existing NHLBI grants (e.g., R01s, R03s, etc.) will be incorporated into the EIA award. However, the EIA does not eliminate the PD/PI from consideration for the following separate sources of NHLBI funding:

• Grants supporting research resources (e.g., P30, R24, or U24 awards);
• Contracts;
• Selected cooperative agreements;
• Grants supporting training, workforce development or diversity building (Note: individual career development grant mechanisms are not permitted except for the NHLBI K24 award [http://www.nhlbi.nih.gov/research/training/programs/established/mid-career-k24]);
• Clinical trials;
• SBIR/STTR grants;
• Conference grants;
• NHLBI program project or center grants (including subprojects)
• Administrative Supplements;
• Applications submitted in response to selected targeted research programs (eligible FOAs to be determined by the NHLBI in consultation with the NHLBAC).

Revised Language:

Since an NHLBI EIA is intended to provide the primary, and most likely sole, source of NHLBI funding on individual grant awards, most existing NHLBI grants (e.g., R01s, R03s, etc.) will be incorporated into the EIA award. However, the EIA does not eliminate the PD/PI from consideration for the following separate sources of NHLBI funding:

• Grants supporting research resources (e.g., P30, R24, or U24 awards);
• Contracts;
• Selected cooperative agreements;
• Grants supporting training, workforce development or diversity building (Note: individual career development grant mechanisms are not permitted except for the NHLBI K24 award [http://www.nhlbi.nih.gov/research/training/programs/established/mid-career-k24]);
• Clinical trials;
• SBIR/STTR grants;
• Conference grants;
• NHLBI program project or center grants (including subprojects)
• Administrative Supplements;

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Narasimhan Danthi, Ph.D.
Division of Cardiovascular Sciences
Telephone: 301-451-5170
Email: ndanthi@nhlbi.nih.gov

Lisa Postow, Ph.D.
Division of Lung Diseases
Telephone: 301-827-7843
Email: postowl@mail.nih.gov

Andrei Kindzelski, Ph.D.
Division of Blood Diseases and Resources
Telephone: 301-827-8275
Email: kindzelskial@mail.nih.gov

Emmanuel Peprah, Ph.D.
Center for Translation Research and Implementation Science
Telephone: 301-496-3620
Email: peprahek@mail.nih.gov

 

---

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

---